The Medical University of South Carolina (MUSC) is the only comprehensive health center in the state. Cancer care is provided through the university’s Hollings Cancer Center, which is the only National Cancer Institute-Designated Cancer Center in South Carolina. Patients seeking treatment at the center are offered the expertise of over 120 physicians and scientists who are all actively involved in cancer research and the latest treatments.
Each mesothelioma patient will benefit from a highly specialized team of experts from a variety of subspecialties working together to create a personalized care plan. First, patients may undergo the center’s in-depth staging program, which enables them to have a better understanding of the cancer’s progression and metastasis and determine the best viable treatment options. Staging may entail a variety of tests, including ultrasounds. Once the team is satisifed with the stage and understanding of an individual’s case, the team will work together to develop an individualized treatment plan, which can entail molecular profiling of the tumors for targeted therapy, minimally invasive surgeries, chemotherapy and a variety of radiation therapies.
Hollings Cancer Center also offers a telemedicine program, allowing thoracic cancer patients to receive consultations and second opinions with other physicians in the region. Patients may also benefit from the clinical trials actively being conducted at the center. Research at the center falls into different categories, like their immunology program, cancer biology program, developmental cancer therapeutics program and the cancer control program. The center has often conducted clinical trials around the latest treatments that have shown promise for mesothelioma like immunotherapy.
- Personalized, targeted therapy
- Minimally invasive thoracic surgery
- Stereotactic radiosurgery
- 3D radiation therapy
- U.S. News & World Report Best Cancer Hospital
- National Cancer Institute Comprehensive Cancer Center designation
- Commission on Cancer accreditation
- Foundation for for the Accreditation of Cellular Therapy designation
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: March 9, 2020
- Mesothelioma Doctors
- Cancer Centers
- Treatment Near You
- Experimental Treatments
- Alternative Treatments
- Clinical Trials
- Caregiver Resources
- Treatment Costs